Trial Profile
A 1-Year, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Heterozygous Familial Hypercholesterolemia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Anacetrapib (Primary)
- Indications Hyperlipoproteinaemia type IIa
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms REALIZE
- Sponsors Merck Sharp & Dohme
- 30 Aug 2017 Results of post-hoc, exploratory analysis evaluate the LDL-C-lowering efficacy of anacetrapib in patient subgroups defined by HeFH mutation type, were presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology.
- 30 May 2015 Status changed from active, no longer recruiting to completed, as reported in The Lancet.
- 30 May 2015 Results published in the Lancet.